Aromatase inhibitors, selective estrogen receptor modulators (SERMs) and selective estrogen receptor downregulators (SERDs) are all endocrine therapy approaches used in the adjuvant and metastatic setting to decrease estrogen signaling in ER+ BC (reviewed in 4). The gene discussed is ESR1; the disease is breast cancer.